10x Genomics Intrinsic Value Calculator – 10x Genomics Surpasses Expectations with Q4 2023 GAAP EPS of -$0.15, Beating Estimates by $0.17.
February 17, 2023
Trending News 🌧️
10x Genomics Intrinsic Value Calculator – 10x Genomics ($NASDAQ:TXG) exceeded expectations in its Q4 2023 GAAP earnings per share (EPS) report, posting a -$0.15 EPS, versus analyst estimates of a -$0.17. This outperformed expectations by $0.17, indicating that the company is making significant progress towards its financial goals. The news of 10x Genomics’ strong performance was met with enthusiasm from investors, who have been watching the company’s progress with interest.
The strong results show that 10x Genomics is continuing to make progress despite the challenges posed by the ongoing pandemic and volatile markets, and provide optimism for the future of the company. Overall, 10x Genomics’ Q4 2023 GAAP EPS of -$0.15 represents a positive result, and demonstrates the company’s ability to deliver on its financial goals in spite of external pressures. With increasing demand for genomic-based technologies, 10x Genomics is poised for continued success in the coming years.
Stock Price
As the market responded favorably to the news, 10X GENOMICS saw a 3.3% increase in its stock price. The stock opened up at $44.3, and closed at $46.3, up from the prior closing price of 44.8. The company’s stock price has since seen a steady rise, as investors welcomed the positive earnings report. This news has been well-received by the market and is expected to have a positive impact on the company’s stock price in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for 10x Genomics. More…
| Total Revenues | Net Income | Net Margin |
| 503.71 | -167.23 | -33.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for 10x Genomics. More…
| Operations | Investing | Financing |
| -58.18 | -106.73 | 35.3 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for 10x Genomics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 996.21 | 220.41 | 6.88 |
Key Ratios Snapshot
Some of the financial key ratios for 10x Genomics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 31.6% | – | -32.0% |
| FCF Margin | ROE | ROA |
| -32.0% | -12.9% | -10.1% |
Analysis – 10x Genomics Intrinsic Value Calculator
At GoodWhale, we have conducted an analysis of 10X GENOMICS‘s financials, and with our proprietary Valuation Line we have calculated that the fair value of 10X GENOMICS share is around $134.9. However, the price of the share is currently significantly lower at $46.3, undervalued by 65.7%. This provides an excellent opportunity for investors to take advantage of a good entry point in the stock. We believe that 10X GENOMICS is an attractive investment option and is a great opportunity to capitalize on the potential upside. More…
Peers
The company’s products include the Chromium System, an integrated solution for genome sequencing and data analysis, and the Visium Spatial Transcriptomics System, amicroarray platform for analyzing transcriptome activity in tissue samples. 10x Genomics has raised $310 million in funding from investors such as Fidelity Investments, Kleiner Perkins, and Google Ventures. 10x Genomics’ main competitors are Certara Inc, Omnicell Inc, and CardioComm Solutions Inc. These companies offer similar products and services to support genomic research.
– Certara Inc ($NASDAQ:CERT)
Certara Inc is a biopharmaceutical company that uses data and technology to improve drug development decisions. The company has a market cap of 2.49B as of 2022 and a Return on Equity of 1.81%. The company’s products and services are used by pharmaceutical, biotechnology, and medical device companies, as well as academic institutions and government agencies.
– Omnicell Inc ($NASDAQ:OMCL)
Omnicell is a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies. Their market cap of 2.49B as of 2022, and ROE of 2.67% indicates a strong and growing company. Omnicell provides solutions that help increase patient safety and improve medication adherence. Their products are used in a variety of settings, including hospitals, long-term care facilities, and retail pharmacies.
– CardioComm Solutions Inc ($TSXV:EKG)
CardioComm Solutions Inc is a medical device company that provides cardiac monitoring and arrhythmia detection solutions. It has a market cap of 2.26M as of 2022 and a return on equity of -59.73%. The company’s products are used in hospitals, clinics, and by individual patients for the remote monitoring of cardiac activity.
Summary
10x Genomics had an impressive quarter ending in Q4 of 2023, with their GAAP EPS coming in at -$0.15, which beat estimates by $0.17. The stock price moved up the same day. For those considering investing in 10x Genomics, they should be encouraged by the company’s strong performance and be aware that the company is likely to continue to achieve their goals and outperform the market. Investors should continue to monitor the company and consider any new developments that may impact its performance.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
